How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID‐19 threat?
Published in British Journal of Haematology
Care of haematology patients in a COVID‐19 epidemic
Published in British Journal of Haematology
Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment
Published in British Journal of Haematology
Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leuka...
...Published in British Journal of Haematology
In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice‐daily radotinib 300 mg ( n = 79) or 400 mg ( n = 81) than with once‐daily imatinib 400 mg ( n = 81) after 12 months. With ≥48 months’ follow‐up, MMR ...
NF‐E2 mutation as a novel cause for inherited thrombocytopenia
...Published in British Journal of Haematology
Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
Published in British Journal of Haematology
The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapid tumour debulking can lead to a treatment‐related...
Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventiv...
Published in British Journal of Haematology
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and exp...
Published in British Journal of Haematology
Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo‐SCT) worldwide. The accumulated experience of allografting in AML over the last four decades has provided critical insights into both the contribution of the conditioning regimen and the graft‐versus‐leukaemia effect to the curative potential of...
The power and potential of integrated diagnostics in acute myeloid leukaemia
Published in British Journal of Haematology
The field of acute myeloid leukaemia (AML) diagnostics, initially based solely on morphological assessment, has integrated more and more disciplines. Today, state‐of‐the‐art AML diagnostics relies on cytomorphology, cytochemistry, immunophenotyping, cytogenetics and molecular genetics. Only the integration of all of these methods allows for a compr...
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how doe...
...Published in British Journal of Haematology
This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia‐negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and healthy volunteers. We performed flow cytometry analysis of P‐selectin expression and integrin beta‐3, activation of gly...
